Categories Analysis, Cannabis, Health Care

Earnings preview: Tilray stock might see big fluctuations post Q3 results

It can be safely said that cannabis is this year’s bitcoin – be it the debates surrounding its regulation or the immense investor interest. And one company has managed to stay above the hundreds of firms that are looking to make a killing out of the glittering prospects of marijuana – Tilray (TLRY).

Tilray is reporting third-quarter earnings results after the market closes on November 13, Tuesday.

Tilray earnings Q3
Photo by Roberto Valdivia on Unsplash

The stock had almost quadrupled in value since going public in July, before paring some of the gains in October. In its first quarterly results since Canada legalized the recreational use of cannabis, the  Nanaimo-based company is expected to report a smaller sequential loss of 14 cents per share. During the second quarter, the company had reported a loss of 17 cents per share.

Meanwhile, revenue had almost doubled year-over-year in Q2 to $9.74 million. With more global acceptance for its products and higher patient demand, Tilray is likely to see another spellbinding revenue growth in the third quarter. Analysts expect Tilray to post revenue of $10 million during the quarter.

However, do not expect the recent legalization in Canada to have a big impact, as it happened quite late into the quarter. On the other hand, look out for management comments on how the company expects to take advantage of these tailwinds to ramp up the production capacity.

Tilray, Canopy Growth could emerge winners in a year’s time

Peers such as Canopy Growth (CGC) and Aurora Cannabis are already investing cash in hand to build better facilities that improve operational efficiency and generate more profits. The Q3 earnings conference call will the right platform for Tilray to convince investors that it is not slacking in this regard.

Tilray is also likely to give updates on its import drug, which has received approval from the US Drug Enforcement Administration for clinical study in patients suffering from a neurological disorder called Essential Tremor. The company,  along with the International Essential Tremor Foundation will fund the study, which will be held at the University of California San Diego Center for Medicinal Cannabis Research.

TLRY stock has an average price target of $135.67, which is at an 18% upside from Monday’s open. The stock is highly volatile and prone to wide fluctuations post earnings. However, for the time being, Tilray looks like the best bet in the marijuana industry.

 

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

Does Unity Software (U) stock has more room to run?

Last month, the IPO market was in a full swing. IPOs of Snowflake (NYSE: SNOW) and JFROG (NASDAQ: FROG) had an impressive opening day in September, the former creating a

PepsiCo (PEP): Steady snacking habits amid pandemic drive strong quarter for beverage giant

PepsiCo Inc. (NASDAQ: PEP) beat market expectations on both revenue and earnings for the third quarter of 2020. The company saw the momentum continue in its snacks business while the

Does the virus-driven boom make Electronic Arts (EA) a good investment?

With more and more people turning to virtual entertainment sources, amid the virus-related movement restrictions, video game publishers like Electronic Arts (NASDAQ: EA) are witnessing unusually high demand. Not surprisingly,

Leave a Reply

Your email address will not be published. Required fields are marked *

Add Comment
Loading...

Cancel
Viewing Highlight
Loading...
Highlight
Close
Top